Haemophilus influenzae Surveillance Report 2012 Oregon Active Bacterial Core Surveillance (ABCs) Center for Public Health Practice Updated: July 2014

Similar documents
Source: Portland State University Population Research Center (

Incidence per 100,

Of 142 cases where sex was known, 56 percent were male; of 127cases where race was known, 90 percent were white, 4 percent were

Incidence per 100,000

Methicillin-Resistant Staphylococcus aureus (MRSA) S urveillance Report 2008 Background Methods

Invasive Bacterial Disease

High Risk Conditions and Vaccination Gaps in Invasive Pneumococcal Disease Cases in Tennessee,

Invasive Bacterial Disease

Invasive Bacterial Diseases in the Arctic. Tom Hennessy, MD, MPH Arctic Investigations Program October 2, 2015 Copenhagen

Influenza-Associated Pediatric Deaths Case Report Form

INVASIVE MENINGOCOCCAL DISEASE (IMD), BACTERIAL/VIRAL MENINGITIS & HAEMOPHILUS INFLUENZAE INFECTIONS IN IRELAND

Epidemiology of Infectious Complications of H1N1 Influenza Virus Infection

Haemophilus influenzae and its invisibility cloak. Anna Strain Virology Supervisor/VPD Reference Center Coordinator June 5, 2018

Influenza-Associated Pediatric Mortality Case Report Form Form Approved OMB No

INVASIVE MENINGOCOCCAL DISEASE (IMD), BACTERIAL/VIRAL MENINGITIS & HAEMOPHILUS INFLUENZAE INFECTIONS IN IRELAND

Pediatric influenza-associated deaths in Arizona,

Streptococcus pneumoniae CDC

INVASIVE MENINGOCOCCAL DISEASE (IMD), BACTERIAL/VIRAL MENINGITIS & HAEMOPHILUS INFLUENZAE INFECTIONS IN IRELAND

Haemophilus influenzae

Annual Epidemiological Report

HAEMOPHILUS INFLUENZAE INVASIVE DISEASE

INVASIVE MENINGOCOCCAL DISEASE (IMD), BACTERIAL/VIRAL MENINGITIS & HAEMOPHILUS INFLUENZAE INFECTIONS IN IRELAND

2016 Vaccine Preventable Disease Summary

INVASIVE MENINGOCOCCAL DISEASE (IMD), BACTERIAL/VIRAL MENINGITIS & HAEMOPHILUS INFLUENZAE INFECTIONS IN IRELAND

2015 Vaccine Preventable Disease Summary

Group B Streptococcus

INVASIVE MENINGOCOCCAL DISEASE (IMD), OTHER BACTERIAL MENINGITIS, HAEMOPHILUS INFLUENZAE & VIRAL MENINGITIS INFECTIONS IN IRELAND

Washoe County Health District Influenza Surveillance Program Final Hospitalization & Death Data

PNEUMONIA : PROMISE FULFILLED? Regina Berba MD FPSMID

2017 Vaccine Preventable Disease Summary

Invasive Neonatal Group-B Streptococcus (GBS) Disease in Wisconsin,

EPIREVIEW INVASIVE PNEUMOCOCCAL DISEASE, NSW, 2002

Health Status of New Mexico 2015

Released February Health Status of New Mexico 2018

New Mexico Emerging Infections Program Overview. Joan Baumbach NM Department of Health September 23, 2016

Appendix B: Provincial Case Definitions for Reportable Diseases

9/12/2018. Pneumococcal Disease and Pneumococcal Vaccines. Streptococcus pneumoniae. Pneumococcal Disease. Adult Track. Gram-positive bacteria

Pneumococcal Vaccine Effectiveness. Steven Black, MD Center for Global Health Cincinnati Children s s Hospital Cincinnati, Ohio USA

The Epidemiology of Invasive Group A Streptococcal Infection and Potential Vaccine Implications: United States,

Haemophilus influenzae, Invasive Disease rev Jan 2018

Haemophilus influenzae type B and Hib Vaccine Chapter 9

Bacterial diseases caused by Streptoccus pneumoniae in children

Journal of Pediatric Sciences

Arctic Council Ministerial April 2009

ACIP Recommendations for Pneumococcal 13-valent Conjugate and 23-valent Polysaccharide Vaccine Use among Adults

Salt Lake County Annual Influenza Report Season Bureau of Epidemiology

Recommendations for Using Pneumococcal Vaccines among Adults

Bacterial Meningitis in the United States,

Disclosure Statement. Encapsulated Bacteria. Functions of the Spleen 10/25/2017. Pharmacist Learning Objectives

Pneumococcal Disease and Pneumococcal Vaccines

Updates on H. pylori research in Alaska. Bethel, Alaska, July 26 th 2016 Michael Bruce MD, MPH AIP/CDC, Anchorage, Alaska

National Institute for Communicable Diseases -- Weekly Surveillance Report --

Pneumococcal Vaccination. Bottom Line. Gangrene from Pneumococcal Bacteremia

Recommendations for Using Pneumococcal Vaccines among Adults

Trends in Pneumonia and Influenza Morbidity and Mortality

QUICK FACTS. Ohio Special Emphasis Report: Fall Injuries among Older Adults A GROWING CONCERN. 1,160 Deaths* 19,461 Hospitalizations**

BCG vaccine and tuberculosis

Chapter 16 Pneumococcal Infection. Pneumococcal Infection. August 2015

IMPACT #: Local Inventory #: form 04. Age at admission: d. mo yr. Postal code:

Experience with Quadrivalent Meningococcal Conjugate Vaccines (MenACWY) in Adolescent Vaccine Programs in the United States and Canada

Pneumococcal Vaccine in Children: current situation

HEALTH PROMOTION AND CHRONIC DISEASE PREVENTION PROGRAM OREGON STATE OF THE HEART AND STROKE REPORT 2001 PREPARED BY.

On behalf of the Infectious Diseases Society of America (IDSA), I am pleased to provide

Pneumococcal infection is one of. Epidemiology of Pneumococcal Disease ...PRESENTATIONS... Based on a presentation by Chris Van Beneden, MD, MPH

Welcome to Pathogen Group 4

Clinical and Molecular Characteristics of Community- Acquired Methicillin-Resistant Staphylococcus Aureus Infections In Chinese Neonates

Influenza A (H1N1)pdm09 in Minnesota Epidemiology

GIHSN-site s experience & Results of season

Antibiotic Resistance Pattern of Blood and CSF Culture Isolates At NHLS Academic Laboratories (2005)

HIV AND LUNG HEALTH. Stephen Aston Infectious Diseases SpR Royal Liverpool University Hospital

Alberta Health and Wellness Public Health Notifiable Disease Management Guidelines August Pneumococcal Disease, Invasive (IPD)

Carga global de la enfermedad neumocócia

The State of Asthma in Arkansas

Monitoring results: goals, strategic objectives and indicators

ABCs Case Report Form Instructions

Pneumococcal vaccines. Safety & Efficacy. Prof. Rajesh Kumar, MD PGIMER School of Public Health Chandigarh

Improving the prevention, diagnosis and clinical management of sepsis

2009 (Pandemic) H1N1 Influenza Virus

NQF-ENDORSED VOLUNTARY CONSENSUS STANDARDS FOR HOSPITAL CARE

Epidemiology of Invasive Group A Streptococcal Infections in the United States,

New Mexico Emerging Infections Program (EIP) Data in Use Health Status Indicators

Streptococcus Pneumoniae

Tuscarawas County Health Department

Appendix A: Disease-Specific Chapters

Annual Communicable Disease Report

2.3 Invasive Group A Streptococcal Disease

Rethinking Recommendations for Use of Pneumococcal Vaccines in Adults

Drug Use And Smoking Among Hospitalized Influenza Patients, Connecticut

Texas Influenza Summary Report, Season (September 28, 2008 April 11, 2009)

Acute Communicable Disease Outbreaks among MSM, 2016

Diphtheria. Vaccine Preventable Childhood Diseases. General information

Fever in Infants: Pediatric Dilemmas in Antibiotherapy

B 型嗜血感冒桿菌感染及 其疫苗 衛生署疾病管制局 中區傳染病防治醫療網 王任賢指揮官

S. Michael Marcy Memorial Lecture

Changing Epidemiology of Bacterial Meningitis in the United States

SURVEILLANCE REPORT. Surveillance of invasive bacterial diseases in Europe.

Pneumococcal vaccines

STOP. Meningococcal Vaccination. Improving Rates in Adolescents and Reducing Racial, Ethnic and Socioeconomic Disparities. Call to Action MENINGITIS

TRENDS IN PNEUMONIA AND INFLUENZA MORBIDITY AND MORTALITY

Transcription:

Haemophilus influenzae Surveillance Report 2012 Oregon Active Bacterial Core Surveillance (ABCs) Center for Public Health Practice Updated: July 2014 Background The Active Bacterial Core surveillance (ABCs) program is a core component of the Emerging Infections Program (EIP) Network sponsored by the Centers for Disease Control and Prevention (CDC). The purpose of the ABCs program is to determine the incidence and epidemiologic characteristics of invasive disease due to Haemophilus influenzae, Neisseria meningitidis, group A streptococcus (GAS), group B streptococcus (GBS), Streptococcus pneumoniae, and methicillin resistant Staphylococcus aureus (MRSA). The entire EIP Network for invasive H. influenzae disease represents almost 42 million persons in 10 surveillance areas around the United States. More information on the EIP/ABCs Network is found at: http://www.cdc.gov/abcs/index.html. In Oregon, the surveillance area for invasive H. influenzae disease comprises the entire state, with a 2012 estimated population of 3,883,735. More information on the Oregon ABCs program is found at: http://public.health.oregon.gov/diseasesconditions/communicabledisease/emerginginfections /Pages/ActiveBacterialCoreSurveillance.aspx. Methods Invasive H. influenzae disease (IHiD) is defined as the isolation of H. influenzae from a normally sterile body site in a resident of Oregon. Since IHiD is reportable in Oregon, hospital laboratories submit sterile site H. influenzae microbiology isolates to the Oregon State Public Health Laboratory for serotyping. Additional cases are identified through regular laboratory record reviews. Isolates are forwarded to a CDC laboratory for confirmation of serotype. Health record reviews of each case provide standardized reports of demographic characteristics, clinical syndrome manifestations, underlying illnesses or conditions, and illness outcome. Surveillance Results Descriptive Epidemiology In 2012, 68 cases of IHiD were reported in Oregon, corresponding to an incidence rate of 1.75/100,000 persons (Figure 1). This is 5 percent higher than the average annual incidence rate in Oregon during the previous five years (1.66/100,000) as well as the most recent national estimate of disease (1.66/100,000). 1 Almost 93 percent of IHiD cases in 2012 were hospitalized, slightly higher than the previous five year average rate of hospitalization (92 percent). Source: Portland State University Population Research Center (http://www.pdx.edu/prc/)

There were 13 IHiD deaths in 2012, for an annual mortality rate of 0.24/100,000, 38 percent higher than the previous five year average in Oregon (0.24/100,000) and 52 percent higher than the national mortality rate projection for IHiD (0.22/100,000). 1 The 2012 case fatality rate for IHiD in Oregon was 19 percent, which is 33 percent higher thanthe figure reported for Oregon from 2007 2011, and 42 percent higher than the national rate of 13 percent in 2012 based on national projections. 1 Forty eight percent of cases were male; of 60 cases where race was known, 97 percent were white; and of 60 cases where ethnicity was known, eight percent were Hispanic or Latino. Consistent with historical patterns, the burden of IHiD in 2012 was highest (.87/ 100,000) among those 65 years of age and older, followed by those 0 4 (2.52/100,000) and 35 64 (1.80/100,000)(Figure 2). Other age groups have remained largely stable over the last few years. Mortality due to IHiD in 2012 was highest among those 65 years of age and older (1.39/100,000); 30 percent higher than the age specific mortality rate in 2011 (1.27/100,000) and 20 percent higher than the age specific previous 5 year average (1.15/100,000). Clinical Manifestations The top two clinical manifestations of IHiD reported in 2012 bacteremic pneumonia (clinical pneumonia with a positive blood culture) and primary bacteremia were reported among 66 percent and 16 percent of cases, respectively (Table 1). The clinical syndrome profile of IHiD has been roughly stable over the six year period. No significant differences were detected between clinical syndromes in 2012 compared to their respective previous 5 year averages. From 2006 2012, clinical manifestation of IHiD was not significantly associated with fatal outcome. 2

Table 1: Percent of IHiD Cases Reporting Common Clinical Syndromes Syndrome 2012 2007 2011 Bacteremic pneumonia 66 64 Primary bacteremia 16 25 Meningitis 10 5 Other 7 7 Some cases report more than 1 syndrome. Other syndrome includes cellulitis, endometritis, epiglottitis, peritonitis, septic abortion, septic arthritis, and sterile abscess. From 2006 2012, bacteremia was the most common presentation among those 5 34 years of age, while bacteremic pneumonia was most common among all other age groups (Figure 3). Bacteremia and meningitis decreased with increasing age (p=0.0002 and p<0.001, respectively), while bacteremic pneumonia increased with age (p<0.001). Underlying Conditions In 2012, the most commonly identified underlying conditions or risk behaviors among IHiD cases were chronic obstructive pulmonary disease (COPD) (35%), diabetes (31%), and cardiovascular disease. With the exception of cancer (p=0.0397) which was less prevalent among cases in 2012 and obesity (p=0.04) which was more prevalent among cases in 2012 than in earlier years, this profile was not significantly different from the profile of underlying conditions seen for cases reported during the previous five years (Table 2). Table 2: Underlying Conditions Reported Among IHiD Cases Underlying Condition 2012 only (n=68) N (%) 2007 2011 (n=317) N (%) Alcohol abuse 5 (7) 22 (7) Asthma 7 (10) 31 (10) Cancer 3 (4) 42 (13) Cardiovascular disease 17 (25) 98 (31) 3

COPD 24 (35) 78 (25) Diabetes 21 (31) 71 (22) Immunosuppression 7 (10) 37 (12) Obesity 14 (21) 36 (11) Smoking 15 (22) 66 (21) None 9 (13) 41 (13) In 2012, cancer, cardiovascular disease, and diabetes were reported most frequently among IHiD cases 65 years and over, while COPD, alcohol abuse, asthma, and smoking were greatest among IHiD cases 35 64 years of age. No underlying risk factors were reported for 13 percent of cases, although this varied considerably by age. Sixty seven percent of cases less than five years of age had no underlying conditions, in contrast to only 7 percent of cases 65 and over. After controlling for age, alcohol abuse was associated with a fatal outcome from IhiD (p=0.0380) and obesity was the only condition to be a significant predictor of clinical manifestation, specifically meningitis (p=0.0059). Serotype Analysis In 2012, serotyping was completed for 64 (94%) H. influenzae isolates causing invasive disease. Of these, there was one nonfatal case of type b in a 67 year old female with multiple underlying conditions (diabetes, COPD, smoker, and cardiovascular disease), hospitalized for three days. Since 1995, there have been 35 cases of serotype b infection, eight of which occurred in children less than five. Until 2010, there had been no cases in this young age group since 2004. Of the remaining IHiD isolates, 42 (66%) were nontypeable and 21 (33%) were of a type other than serotype b (Figure 4). This was not significantly different from the serotype profile of cases reported during the previous five years. Among each age group, the most common serotype was 4

nontypeable, followed by non b and b serotypes (Figure 5). None of the serotypes were significantly associated with fatal outcome. After controlling for age, non b serotypes were significantly associated with bacteremia. Non b cases were positively associated with bacteremia (OR 2.0; [CI] 1.1, 3.6). Discussion H. influenzae serotype b (Hib) was once the leading cause of bacterial meningitis and a common cause of invasive bacterial disease among children less than 5 years of age in the United States. With the introduction of Hib vaccines during the mid to late 1980s, the incidence of invasive Hib disease in children less than 5 has decreased significantly leading to a notable change in the overall epidemiology of IHiD. 2 There has been increased recognition of non serotype b and nontypeable cases in persons over 5 years of age, especially among those 65 years of age or older. In Oregon, our surveillance data confirm this overall trend. We will continue to monitor these trends and work with other ABCs sites to better characterize the changing epidemiology of IHiD. References 1. Centers for Disease Control and Prevention. 2012. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Haemophilus influenzae, 2010. Available via the Internet: http://www.cdc.gov/abcs/reports findings/surv reports.html. Accessed 1 July 2014. 2. Centers for Disease Control and Prevention. Achievements in Public Health, 1990 1999 Impact of Vaccines Universally Recommended for Children United States, 1990 1999. MMWR 1999; 48(12):243 8. 5